Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Contravir Pharmaceuticals Inc (NASDAQ: CTRV).

Full DD Report for CTRV

You must become a subscriber to view this report.


Recent News from (NASDAQ: CTRV)

ContraVir: A Speculative Contrarian Bet With Lots Of Upside Potential
Introduction ContraVir Pharmaceuticals ( CTRV ) is a clinical-stage biotech company focused on the development of small-molecule antivirals for Chronic Hepatitis B. ContraVir has developed a strong Hepatitis B pipeline consisting of two small-molecule antiviral agents. With a novel cycloph...
Source: SeekingAlpha
Date: May, 01 2018 12:34
ContraVir Pharmaceuticals Announces New Data Presented at the 2018 International Liver Congress(TM)
EDISON, N.J., April 12, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV) announced today, the presentation of new data on TXL...
Source: GlobeNewswire
Date: April, 12 2018 12:46
ContraVir Pharmaceuticals Appoints Two New Hepatitis B Experts to Scientific Advisory Board
EDISON, N.J., April 09, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the appointment of leading researchers in hepatitis B virus (HBV) to ...
Source: GlobeNewswire
Date: April, 09 2018 06:00
ContraVir Pharmaceuticals to Present Three Posters at the 53rd Annual International Liver Congress(TM)
EDISON, N.J., April 03, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced today that three abstracts have been acce...
Source: GlobeNewswire
Date: April, 03 2018 06:00
Your Daily Pharma Scoop: Clovis Oncology Gets A Boost, Mesoblast Positive Data, Kadmon's Updated Results
Analysis of top Seeking Alpha coverage: Clovis Oncology Today we will discuss Clovis Oncology ( CLVS ). Clovis Oncology have had a good run this week, gaining more than 11%. The stock though still remains down more than 21% in the last six months and well-off its 52-week high of $99.45. T...
Source: SeekingAlpha
Date: February, 24 2018 08:00
ContraVir's TXL an Orphan Drug in U.S. for pediatric HBV infection; shares up 7%
The FDA designates ContraVir Pharmaceuticals' ( CTRV +7.4% ) TXL (tenofovir exalidex) an Orphan Drug for the treatment of chronic hepatitis B virus (HBV) infection in a pediatric (ages 0 - 11 years old) population. More news on: ContraVir Pharmaceuticals, Inc., Healthcare stocks news, ...
Source: SeekingAlpha
Date: February, 22 2018 12:01
ContraVir Pharmaceuticals Announces TXL(TM) Has Been Granted Orphan Drug Designation for the Treatment of HBV in a Pediatric Population
EDISON, N.J., Feb. 22, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Dr...
Source: GlobeNewswire
Date: February, 22 2018 08:00
ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until March 9, 2018
3 of 4 Proposals pass with stockholder approval Annual Meeting adjourned solely with respect to Proposal 4 - Approval of Reverse Stock Split EDISON, N.J., Feb. 21, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the dev...
Source: GlobeNewswire
Date: February, 21 2018 16:30
Your Daily Pharma Scoop: Akebia Update, Rexahn Data, Concert Commences Enrollment
Analysis of top Seeking Alpha coverage: Akebia Today we will focus on Akebia Therapeutics ( AKBA ) after the company provided an update to investors on its late-stage vadadustat studies. Vadadustat is AKBA’s lead product candidate being evaluated for the treatment of anemia assoc...
Source: SeekingAlpha
Date: February, 14 2018 08:00
ContraVir to use abbreviated regulatory path for HBV candidate TXL; shares up 26%
The FDA has signed off on allowing ContraVir Pharmaceuticals ( CTRV +26% ) to use the abbreviated 505(b)(2) regulatory pathway for HBV candidate TXL, allowing it to use data generated by others. More news on: ContraVir Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, ...
Source: SeekingAlpha
Date: February, 12 2018 13:14

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-170.680.66030.680.6476,114
2018-08-160.6210.65880.710.6169126,038
2018-08-150.680.630.700.61393,884
2018-08-140.710.68490.710.6821,172
2018-08-130.710.69990.710.685209,065

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1725,20233,19675.9188Short
2018-08-165,68727,41320.7456Cover
2018-08-1573,663140,31252.4994Short
2018-08-145,0476,29980.1238Short
2018-08-1330,58660,70250.3871Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CTRV.


About Contravir Pharmaceuticals Inc (NASDAQ: CTRV)

Logo for Contravir Pharmaceuticals Inc (NASDAQ: CTRV)

We are a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus, or VZV.

 

Contact Information

 

 

Current Management

  • James Sapirstein / CEO
  • William Hornung / CFO
  • Gary S. Jacob / Chairman
    • Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May until January and a director from October until January . Dr. Jacob currently serves as a director of Trovagene, Inc., a diagnostics company. Dr. Jacob has over twentyfive years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research amp development, operations and business development. Prior to , Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from to was Director of Functional Genomics, Corporate Science amp Technology, at Monsanto Company. Dr. Jacob also served from to as Director of Glycobiology at G.D. Searle Pharmaceuticals Inc. During the period of to , he was Manager of the G.D. Searle Glycobiology Group at Oxford University, England.
  • Timothy Block / Director
    • Dr. Block is Professor of Microbiology and Immunology, Drexel University College of Medicine and Director of its Drexel Institute for Biotechnology and Virology Research, and is also the Cofounder and President of the Hepatitis B Foundation HBF and its Baruch S. Blumberg Institute formerly called the Institute for Hepatitis and Virus Research , the nation s leading nonprofit organizations dedicated to finding a cure for hepatitis B and improving the lives of those affected worldwide through research, education and patient advocacy. Dr. Block is also President and CEO of the Pennsylvania Biotechnology Center. Dr. Block has been a member of medical school faculties as a professional researcher for more than years, publishing more than papers, U.S. patents, and since , has led or coled more than million in research funding. Honors include an honorary Medical Doctorate Bulgarian Academy of Medicine the Lifetime Achievement Award from the Centrals Bucks Chamber of Commerce named one the regions Most Outstanding People of the Century by the Daily Intelligencer Distinguished Service Recognition from the National Cancer Institute s Early Detection Research Network and a Special Citation from the U.S. House of Representatives in recognition of outstanding achievements. Dr. Block has given frequent testimony to the U.S. Congress and State legislatures has served on U.S. FDA and numerous NIH panels as well as commercial boards including the Bristol Myers Squibb Entecavir Advisory Board. In , Dr. Block was named an elected Fellow of the American Association for the Advancement of Science AAAS .
  • John P. Brancaccio / Director
    • Since April , Mr. Brancaccio has been the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies. Mr. Brancaccio served as a director of Callisto Pharmaceuticals, Inc. from April until its merger with Synergy Pharmaceuticals, Inc. in January and has been a director of Tamir Biotechnology, Inc. formerly Alfacell Corporation since April , as well as a director of Trovagene, Inc. since December , Synergy Pharmaceuticals Inc. since July and ContraVir Pharmaceuticals, Inc. since December .
  • Christopher McGuigan / Director
    • Since , Dr. McGuigan has been Professor of Medicinal Chemistry, Welsh School of Pharmacy, Cardiff University, UK. He is also Deputy Pro ViceChancellor Cardiff University, with responsibility for research. Dr. McGuigan is immediate past president of the International Society for Antiviral Research. Dr. McGuigan has over publications and patents. Dr. McGuigan has Chairman of Departmental Research Committee and Director of Research, Head of Medicinal Chemistry. Dr. McGuigan currently serves as a director of Trovagene, Inc.

Current Share Structure

  • Market Cap: $22,766,925 - 05/15/2018
  • Authorized: 120,000,000 - 12/31/2013
  • Issue and Outstanding: 84,951,212 - 03/16/2018

 


Recent Filings from (NASDAQ: CTRV)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 13 2018
Annual transition reports filed under rule 13a-10 or 15d-10 of the Securities Exchange Act
Filing Type: 10-KTFiling Source: edgar
Filing Date: March, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 09 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: February, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 22 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: February, 21 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 21 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 09 2018

 

 


Daily Technical Chart for (NASDAQ: CTRV)

Daily Technical Chart for (NASDAQ: CTRV)


Stay tuned for daily updates and more on (NASDAQ: CTRV)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CTRV)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CTRV is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CTRV and does not buy, sell, or trade any shares of CTRV. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/